Investors

2017 News Releases

Keyword Search
 
2017
12/11/17
Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
12/11/17
New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
12/10/17
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A
12/09/17
ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
11/27/17
U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B
11/21/17
Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/01/17
Bioverativ to Present at the Credit Suisse 2017 Healthcare Conference
11/01/17
Bioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting
10/31/17
Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE®
10/26/17
Bioverativ Reports Third Quarter 2017 Performance
10/02/17
Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
09/28/17
Bioverativ to Report Third Quarter 2017 Financial Results on October 26, 2017
09/06/17
Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia and Sickle Cell Disease
08/30/17
Bioverativ to Present at Citi’s 12th Biotech Conference
08/24/17
Bioverativ and Invicro Form Novel, Advanced Imaging Collaboration Focused on Improving Management of Joint Health in People with Hemophilia
08/02/17
Bioverativ Reports Second Quarter 2017 Performance
07/07/17
Bioverativ to Report Second Quarter 2017 Financial Results on August 2, 2017
07/06/17
New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care
07/06/17
Bioverativ and Sobi Highlight Commitment to Improving Care for People with Hemophilia at ISTH 2017 Congress
06/28/17
Bioverativ Completes Acquisition of True North Therapeutics
06/12/17
Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A
06/05/17
Bioverativ to Present at the Jefferies 2017 Healthcare Conference
05/23/17
Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics
05/15/17
Bioverativ Appoints Geno J. Germano to Company’s Board of Directors
05/10/17
Bioverativ to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
05/03/17
Bioverativ Reports First Quarter 2017 Results
04/17/17
Bioverativ Joins in Celebration of World Hemophilia Day
04/10/17
Bioverativ Appoints Tim Harris Executive Vice President, Research and Development
04/06/17
Bioverativ to Report First Quarter 2017 Financial Results on May 3, 2017
03/02/17
Anna Protopapas to Join Bioverativ Board of Directors
03/02/17
Long-term Safety and Efficacy Extension Study Data of ALPROLIX® for Hemophilia B Published in Thrombosis and Haemostasis
02/23/17
Bioverativ to Present at the Cowen and Company 37th Annual Health Care Conference
02/08/17
Bioverativ to Present at the Leerink Partners 6th Annual Global Healthcare Conference
02/02/17
Long-Term Safety and Efficacy Data of Extended Half-Life Therapy ALPROLIX® in Children with Hemophilia B Published in The Lancet Haematology
02/01/17
Bioverativ Launches as Global Biotechnology Company Dedicated to Meaningful Progress in Hemophilia

Full list of Bioverativ press releases